Most linked-to pages

Showing below up to 50 results in range #451 to #500.

451. Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.22 (7 links)
452. Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.27 (7 links)
453. Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (f) (7 links)
454. Reference:USA 21 CFR Part 50 09-Apr-2025 § 812.36 (c) (7 links)
455. Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.6 (7 links)
456. Reference:USA 21 CFR Part 812 09-Apr-2025 Subpart G (7 links)
457. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.1 (7 links)
458. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.110 (b) (7 links)
459. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (a) (2) (7 links)
460. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (a) (3) (7 links)
461. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (a) (3) (ii) (7 links)
462. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (b) (5) (7 links)
463. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.140 (d) (7 links)
464. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.145 (7 links)
465. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (1) (7 links)
466. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (2) (7 links)
467. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (3) (7 links)
468. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (4) (7 links)
469. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (5) (7 links)
470. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (1) (7 links)
471. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (1) - (3) (7 links)
472. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (5) (7 links)
473. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (7)-001 (7 links)
474. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (7)-002 (7 links)
475. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (8) (7 links)
476. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.25 (7 links)
477. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.36 (7 links)
478. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (j) (7 links)
479. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (m) (7 links)
480. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (o) (7 links)
481. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.40 (7 links)
482. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.43 (7 links)
483. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.43 (c) (4) (7 links)
484. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.43 (c) (5) (7 links)
485. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.45 (7 links)
486. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (a) (7 links)
487. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) (7 links)
488. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-001 (7 links)
489. Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-002 (7 links)
490. Reference:USA 42 CFR Part 11 09-Apr-2025 § 11.10 (b) (5) (7 links)
491. Reference:USA 45 CFR Part 46 09-Apr-2025 Subpart D (7 links)
492. Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.117 (7 links)
493. Reference:USA Expedited Review: Categories of Research that may be Reviewed Through an Expedited Review Procedure 1998 - (7 links)
494. Reference:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 III A. ; IV. (7 links)
495. Reference:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; Evaluation (7 links)
496. Reference:USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 Introduction ; III. B. ; IV. (7 links)
497. Reference:USA FDA Guidance for Industry - Computerized Systems Used in Clinical Investigations May-2007 IV (7 links)
498. Reference:USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020 Q15 (7 links)
499. Reference:USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013 III 2. (7 links)
500. Reference:USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013 III 4. (7 links)